A5000475484- Cancer Immunotherapy and Biomarkers
- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Colorectal Cancer Treatments and Studies
- Gastric Cancer Management and Outcomes
- Genetic factors in colorectal cancer
- Esophageal Cancer Research and Treatment
- Lymphoma Diagnosis and Treatment
- COVID-19 Clinical Research Studies
- Inflammatory Biomarkers in Disease Prognosis
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Liver Disease Diagnosis and Treatment
- Liver Diseases and Immunity
- Cancer Mechanisms and Therapy
- Hepatitis B Virus Studies
- Colorectal Cancer Screening and Detection
- Colorectal and Anal Carcinomas
- Chronic Lymphocytic Leukemia Research
- Gastrointestinal Tumor Research and Treatment
- Immune Cell Function and Interaction
- Neutropenia and Cancer Infections
- Blood groups and transfusion
- Bladder and Urothelial Cancer Treatments
Cornell University
2019-2025
Weill Cornell Medicine
2019-2025
NewYork–Presbyterian Brooklyn Methodist Hospital
2020-2025
Presbyterian Hospital
2019-2023
New York Hospital Queens
2019-2022
NewYork–Presbyterian Hospital
2019-2022
Lincoln Medical Center
2022
Civil Service
2022
Assistance Publique – Hôpitaux de Paris
2022
Hôpital Cochin
2022
Systemic inflammation is a hallmark of cancer, and it has pivotal role in hepatocellular carcinoma (HCC) development progression. We conducted retrospective study including 362 patients receiving immune check-point inhibitors (ICIs) across three continents, evaluating the influence neutrophiles to lymphocytes ratio (NLR), platelets (PLR), prognostic nutritional index (PNI) on overall (OS), progression free survival (PFS), radiologic responses. In our treated with immunotherapy, median OS PFS...
Immune checkpoint inhibitors (ICIs) have revolutionized treatment of advanced hepatocellular carcinoma. Integrated use transarterial chemoembolization (TACE), a locoregional inducer immunogenic cell death, with ICI has not been formally assessed for safety and efficacy outcomes.From retrospective multicenter dataset 323 patients treated ICI, we identified 31 who underwent >1 TACE 60 days before or concurrently, nivolumab at single center. We derived propensity score-matched cohort 104 based...
In patients with locally advanced cancer without distant metastases, the neoadjuvant setting presents a platform to evaluate new drugs. For mismatch repair proficient/microsatellite stable (pMMR/MSS) colon and rectal cancer, immunotherapy has shown limited efficacy. Herein, we report exceptional responses observed botensilimab (BOT), an Fc-enhanced next-generation anti-CTLA-4 antibody, alongside balstilimab (BAL; anti-PD-1 antibody) in two pMMR/MSS cancer. The histological pattern of rapid...
Immunotherapy has been widely used in the treatment of several solid and hematologic malignancies. Checkpoint inhibitors have forefront cancer immunotherapy recent years. Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) programmed cell death 1 (PD-1) pathway are prototypic checkpoint targets for immunotherapy. When combined, CTLA-4 PD-1 work synergistically, but with increased probability toxicity. The following case represents an unusual adverse effect combined ipilimumab nivolumab...
Immune checkpoint inhibitors (ICI) have shown positive results in patients with hepatocellular carcinoma (HCC). As liver function contributes to prognosis, its precise assessment is necessary for the safe prescribing and clinical development of ICI HCC. We tested accuracy albumin-bilirubin (ALBI) grade as an alternative prognostic biomarker Child-Turcotte-Pugh (CTP). In a prospectively maintained multi-centre dataset HCC patients, we assessed safety efficacy across varying levels dysfunction...
Background Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment a real-world setting lacking. Patients methods We performed an international, multicenter observational study to confirm safety efficacy nivolumab 233 patients treated outside clinical trials from eight centers North America, Europe Asia. Results received for Barcelona Clinic Liver Cancer stage C (n = 191, 92.0%) Child-Pugh (CP)...
Immune checkpoint inhibitor (ICI) therapy is an expanding therapeutic option for hepatocellular carcinoma (HCC). Antibiotics (ATB) taken prior to or early during ICI can impact immunotherapy efficacy across indications; however, the effect of ATB undefined in HCC.In a large international cohort 450 recipients from Europe, North America, and Asia, we categorized patients according timing focusing on exposure within -30 +30 days (early period [EIOP]). EIOP was evaluated association with...
117 Background: There is an unmet need to have effective systemic immunotherapeutic option for patients with mismatch repair proficient/microsatellite stable (pMMR/MSS) colorectal cancer. The neoadjuvant platform presents ideal setting as a window of opportunity evaluate new drugs. NEST-1 trial explored the safety and efficacy botensilimab (BOT), Fc-enhanced next-generation anti–CTLA–4 antibody, alongside balstilimab (BAL; anti-PD-1 antibody) in colon rectal cancer who were candidates...
207 Background: Checkpoint inhibitors (CPI) have been transformative for localized dMMR CRC (microsatellite instability-high [MSI-H]), but not pMMR stable [MSS]). The combination of BOT, a novel Fc-enhanced multifunctional CTLA-4 antibody, and BAL, an anti-PD-1 has demonstrated significant activity in metastatic CRC. We examined this dual CPI therapy patients with MSI-H MSS Methods: This is single arm trial neoadjuvant BOT 75 mg/m 2 (day 1) BAL 240 every weeks x2 (NEST1) or x4 (NEST2) who...
28 Background: Colorectal cancer (CRC) is the fourth most common cause of death and cancer-related mortality expected to increase exponentially. Ethnic minorities, in particular African Americans, have increased from CRC. Although multifactorial, differences somatic gene mutations could contribute these racial discrepancies. Mutations critical oncogene KRAS are associated with worse prognosis Recent literature suggests that CRC patients, more frequently found Americans compared Caucasians....
Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that approved by Food and Drug Administration for treatment of metastatic non-small lung cancer, melanoma, relapsed Hodgkin lymphoma advanced renal cancer. We report a rare case myxedema crisis induced nivolumab in patient with squamous carcinoma lung.Fifty three-year old woman currently on presented diffuse facial tongue swelling, slurred speech, depressed mentation, fatigue weakness. Initial evaluation revealed...
Different approaches are available after the progression of disease (PD) to immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC), including continuation ICI, treatment switching tyrosine kinase (TKIs) and cessation anticancer therapy. We sought characterise relationship between radiological patterns survival post-ICI, also appraising strategies.
Antibiotic use can result in reduced efficacy of immune checkpoint blockade (ICB), presumably because dysbiosis the intestinal microbiome. We sought to determine precise temporal relation between antibiotic therapy and its possible effects on ICB efficacy. also investigated histologic changes tumor microenvironment secondary antibiotics use.This was a single institution retrospective study that evaluated impact outcomes patients with advanced or metastatic malignancy who were treated ICB....
The impact of corticosteroid therapy (CT) on efficacy immune checkpoint inhibitors (ICI) is undefined in hepatocellular carcinoma (HCC). We evaluated whether CT administered at baseline (bCT) or concurrently with ICI (cCT) influences overall (OS), progression-free survival (PFS) and response rates (ORR) 341 patients collected across 3 continents. Of 304 eligible patients, 78 (26%) received > 10 mg prednisone equivalent daily either as bCT (n=14, 5%) cCT (n=64, 21%). Indications for...
BACKGROUND A well-recognized class effect of immune checkpoint inhibitors (ICI) is immune-related adverse events (IrAEs) ranging from low grade toxicities to life-threatening end organ damage requiring permanent discontinuation ICI. Deaths are reported in < 5% patients treated with There are, however, no reliable markers predict the onset and severity IrAEs. We tested association between neutrophil-lymphocyte ratio (NLR) platelet-lymphocyte (PLR) at baseline development clinically...
Abstract The availability of immune checkpoint inhibitors (ICIs) for the management advanced hepatocellular cancer (HCC) has changed treatment paradigm. There are emerging questions regarding efficacy subsequent anticancer therapies. primary aim this retrospective, multicenter study was to examine types received after ICIs and assess impact on post‐ICI survival. We established an international consortium 11 tertiary‐care referral centers located in USA (n = 249), Europe 74), Asia 97),...
Benign Multicystic Peritoneal Mesothelioma (BMPM) is a rare condition that arises from the abdominal peritoneum. Fewer than 200 cases have been reported worldwide. BMPM usually affects premenopausal women and extremely in men. Many factors are suspected to contribute its development, such as previous surgery, endometriosis, familial Mediterranean fever. The main management surgical resection; however, it estimated recurrence rate up 50%. Malignant transformation rare. We report case series...
Background: Antibiotic exposure has been associated with worse outcomes immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump (PPIs) and histamine-2-receptor antagonists (H2RAs), are also known disrupt microbiome, but data on their association ICI conflicting. Methods: We conducted a retrospective, multicenter, international cohort study including 314 hepatocellular carcinoma (HCC)...